A TRANSITION FROM MONOTHERAPY TO COMBINATION THERAPY.

ContraFect Corporation, a New York-based biotechnology company, has assembled one of the most talented management and scientific teams in the industry. We are committed to developing technologies, treatments, and products that will target and kill the most virulent and resistant microorganisms—including gram-positive bacteria, such as Staphylococcus (MRSA), and viruses, such as Influenza.
Microscope
Current therapy focuses on monotherapy—meaning the use of one drug at a time. ContraFect believes that this approach exerts an evolutionary pressure on mutant strains and promotes the formation of drug-resistant pathogens. The Company believes that treatment of drug-resistant pathogens requires new methods—those focusing on:

(a) combination therapy: attacking multiple targets on pathogens simultaneously using multiple Monoclonal Antibodies (Mabs) and Bactericidal Enzymes (Lysins), so that no single mutation or genetic reassortment can result in escape from therapy, or:

(b) single Mab or Lysin therapy to conserved targets: targeting specific parts of bacteria and viruses that do not mutate so that a single Mab or Lysin can be used without worry of generating resistance.